Helix Acquisition Corp. III Class A Ordinary Shares
HLXC
NASDAQ Global Market10.58
USD
+0.38
- -
CIK
0002099656
ISIN
KYG4444S1075
CUSIP
G4444S107
Return %
Stock
S&P500
1Y
5.80
18.21
3Y
5.80
63.29
5Y
5.80
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Bihua Chen
- Full Time Employees
- 3
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 200 Clarendon Street Boston MA United States of America 02116
- IPO Date
- Jan 23, 2026
- CIK
- 0002099656
- Website
- tradretfs.com
- Similar Companies
- Business
- Helix Acquisition Corp. III is a Cayman Islands–incorporated blank-check company (SPAC) formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations or similar business combinations, with an explicit focus on opportunities in healthcare and healthcare-related industries; it operates as a vehicle to acquire or merge with one or more enterprises in the biotechnology, medical technology and life sciences sectors, and intends to pursue its business combination in the United States and globally through its initial public offering and subsequent transactions. The company is led by Chief Executive Officer and Chairperson Bihua Chen and Chief Financial Officer and Chief Operating Officer Caleb Tripp, with sponsorship from Helix Holdings III LLC, an affiliate of Cormorant Asset Management, and is positioned to leverage healthcare expertise and investments in its target search and execution strategy. Founded in 2025, HLXC is headquartered in Paris, Île-de-France, FR, and seeks to deploy net proceeds from its IPO toward identifying and consummating a qualifying business combination in the healthcare field, while continuing to evaluate opportunities across related segments. Latest major changes include the pricing and closing of the company’s initial public offering for gross proceeds of approximately $150–$172.5 million (depending on underwriting options exercised), with an underwriter’s overallotment option potentially expanding the capital pool; this aligns with strategic emphasis on healthcare brands, devices, diagnostics, therapies, and life-science services. The latest changes also reflect the anticipated listing and market debut in 2026, increased visibility through the IPO, and ongoing refinements to governance and financial management as the SPAC positions itself to execute a healthcare-focused transaction in the near term. The company’s primary products and services are the SPAC vehicle’s offerings: structuring and pursuing strategic acquisitions or business combinations in the healthcare sector; and providing access to a publicly traded vehicle for investors seeking exposure to healthcare opportunities via the HLXC ticker on the Nasdaq market. In addition to its core SPAC functions, it maintains a pipeline-oriented approach to target identification, diligences, and regulatory compliance, along with investor relations and reporting aligned to public markets standards. HLXC’s geographic footprint centers on the United States for target activity and deal execution, with corporate oversight and sponsorship tied to international entities, and the company remains open to cross-border opportunities and multi-entity transactions in collaboration with healthcare entities and financial partners. The description above reflects the company’s mandate, founding details, headquarters, and the latest developments in its fundraising and strategic positioning for healthcare-focused mergers and acquisitions. Based on the company’s stated focus, potential investment themes include biotech therapeutics, medical devices and diagnostics, digital health platforms, contract research and manufacturing organizations, life sciences tools and services, and related healthcare infrastructure opportunities. The firm’s reporting and disclosures emphasize alignment with investor expectations for SPACs and healthcare deal activity, including updates on the status of the IPO, underwriter options exercised, and progress toward identifying a consummation target. The descriptions are intended for inclusion in financial databases and investment research platforms that catalog SPACs and healthcare-focused corporate actions.
HLXC (NASDAQ:HLXC) Stock Price Down 0.7% – Should You Sell?
Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares